Dna methylation of the glucocorticoid receptor gene predicts substance use in adolescence: longitudinal data from over 1000 young individuals

ABSTRACT Early life stress has been linked to increased methylation of the Nuclear Receptor Subfamily 3 Group C Member 1 (_NR3C1_) gene, which codes for the glucocorticoid receptor.

Moreover, early life stress has been associated with substance use initiation at a younger age, a risk factor for developing substance use disorders. However, no studies to date have

investigated whether _NR3C1_ methylation can predict substance use in young individuals. This study included adolescents 13–14 years of age that reported no history of substance use at

baseline, (_N_ = 1041; males = 46%). Participants contributed saliva DNA samples and were followed in middle adolescence as part of KUPOL, a prospective cohort study of 7th-grade students in

Sweden. Outcome variables were self-reports of (i) recent use, (ii) lifetime use, and (iii) use duration of (a) alcohol, (b) tobacco products, (c) cannabis, or (d) any substance. Outcomes

were measured annually for three consecutive years. The predictor variable was DNA methylation at the exon 1 F locus of _NR3C1_. Risk and rate ratios were calculated as measures of

association, with or without adjustment for internalizing symptoms and parental psychiatric disorders. For a subset of individuals (_N_ = 320), there were also morning and afternoon salivary

cortisol measurements available that were analyzed in relation to _NR3C1_ methylation levels. Baseline _NR3C1_ hypermethylation associated with future self-reports of recent use and use

duration of any substance, before and after adjustment for potential confounders. The overall estimates were attenuated when considering lifetime use. Sex-stratified analyses revealed the

strongest association for cigarette use in males. Cortisol analyses revealed associations between _NR3C1_ methylation and morning cortisol levels. Findings from this study suggest that

saliva _NR3C1_ hypermethylation can predict substance use in middle adolescence. Additional longitudinal studies are warranted to confirm these findings. SIMILAR CONTENT BEING VIEWED BY

OTHERS ALCOHOL CONSUMPTION, DEPRESSION, OVERWEIGHT AND CORTISOL LEVELS AS DETERMINING FACTORS FOR _NR3C1_ GENE METHYLATION Article Open access 24 March 2021 DNA METHYLATION AND GENERAL

PSYCHOPATHOLOGY IN CHILDHOOD: AN EPIGENOME-WIDE META-ANALYSIS FROM THE PACE CONSORTIUM Article 16 November 2022 METHYLATION AND EXPRESSION OF GLUCOCORTICOID RECEPTOR EXON-1 VARIANTS AND

FKBP5 IN TEENAGE SUICIDE-COMPLETERS Article Open access 13 February 2023 INTRODUCTION Adolescence represents a critical period for brain maturation and development that, if disrupted by

substance use, can enhance the risk for developing substance use disorders later in life [1]. Individuals who initiate substance use before the age of 14 have an estimated 34% prevalence

rate of lifetime abuse and, as individuals continue to mature until the age of 21, the risk drops 4–5% for each year that substance use initiation is delayed [2, 3]. Exposure to stressful

life events in childhood is a strong risk factor for a younger age of drug use onset and the emergence of problematic substance use already in adolescence [4,5,6,7,8]. However, the molecular

mechanisms that underlie the association between early life stress and adolescent substance use remain largely unknown. Stress activates the hypothalamic–pituitary–adrenal (HPA) axis and

leads to the production of glucocorticoids, e.g., cortisol in humans [9]. Glucocorticoids serve numerous functions essential to survival, including metabolic and inflammatory processes, and

they mediate the behavioral responses to stress [9]. Glucocorticoids also act in a negative feedback loop to suppress HPA activation and promote homeostasis when the stressor has subsided

[9]. On the molecular level, this negative feedback is achieved by binding of glucocorticoids to glucocorticoid receptors, transcription factors encoded by the Nuclear Receptor Subfamily 3

Group C Member 1 (_NR3C1_) gene [9]. Preclinical rodent models of early life stress, e.g., based on maternal separation, have linked prolonged activations of the HPA axis with the

development of anxiogenic and fearful behaviors [10]. The negative effects of maternal separation were found to be mediated by epigenetic changes in the rodent _Nr3c1_ gene. Specifically, a

relationship was found between maternal separation and DNA hypermethylation of the neuron-specific _Nr3c1_ promoter, at the exon 17 locus, which interferes with transcription factor binding

of the nerve growth factor-induced protein A (NGFI-A) and leads to decreased expression of _Nr3c1_ [11]. A number of human studies have also found that _NR3C1_ hypermethylation at the

equivalent human locus (i.e., exon 1 F) is associated with exposure to early life stress, including childhood maltreatment, parental loss, or parental disease, and being the victim of

bullying [12,13,14,15,16,17,18,19]. Moreover, several human studies have linked _NR3C1_ methylation levels with changes in HPA functioning, e.g., as reflected by aberrant cortisol stress

responses [15, 17, 20,21,22]. There is also increasing evidence demonstrating that an altered HPA axis, e.g., due to early life adversity, can contribute to key aspects of substance use

disorders [23, 24]. Specifically, a dysregulated HPA axis can enhance a drug’s positive reinforcing effects, thus promoting continued use that is necessary for the development of dependence

[25]. A dysregulated HPA axis can also strengthen the negative effects associated with abstinence and withdrawal, thus contributing to relapse and the maintenance of substance use through

negative reinforcement [26, 27]. Glucocorticoids, in particular, interact with various neurotransmitter and neuropeptide systems implicated in substance use disorders and are thought to play

a critical role in addiction, partly by modulating the formation of drug-related memories [28, 29]. A specific and causal role of NR3C1 in addictive behaviors has been demonstrated in

preclinical studies, where selective inactivation of _Nr3c1_ in mouse dopaminoceptive neurons was found to reduce the motivation of mice to self-administer cocaine [30]. Similarly,

pharmacological compounds targeting NR3C1, including NR3C1 antagonists and modulators, have been found to possess therapeutic properties in intervention studies for alcohol dependence [31,

32]. However, no large-scale human studies to date have employed a longitudinal approach to examine the association between _NR3C1_ methylation at the exon 1 F locus and later substance use

risk among adolescent individuals. The presented data, which derive from over 1000 adolescents with no reported history of substance use at baseline (i.e., at 13–14 years of age), suggest

that saliva _NR3C1_ hypermethylation can predict future substance use in middle adolescence. METHODS STUDY PARTICIPANTS The study participants were part of the KUPOL study, a prospective

cohort study that included _N_ = 3959 adolescents attending the 7th grade (13–14 years of age) of compulsory school in both urban and rural areas of eight regions in southern and central

Sweden. Detailed information on the KUPOL study has been published elsewhere [33]. In brief, participant recruitment took place during school years 2013–2014 and 2014–2015. Data were

collected through self-administered questionnaires that were completed annually by adolescents and their parents during the following three years, i.e., until 16–17 years of age. National

registries were also used to retrieve medical and socio-economic information on students and their parents. A sample of KUPOL students also contributed saliva specimens (_N_ = 1315). In the

present study, we analyzed participants who were naïve to any substance use at baseline and had successful measurements of _NR3C1_ methylation (_N_ = 1041). The KUPOL study was approved by

the Stockholm Ethics Review Board (reference numbers: 2012/1904-31/1 and 2016/1280-32). All students agreed to participate in the study and all legal guardians gave written informed consent.

SUBSTANCE USE DATA Self-reported substance use data were available for cigarettes, snus (a smokeless tobacco product popular in Scandinavia), alcohol, and cannabis. In the analyses, we also

included the compound substance measures of “tobacco use” and “any substance use”. “Tobacco use” was defined as cigarette smoking and/or snus use, and “any substance use” was defined as any

report of using tobacco, alcohol, or cannabis. For each substance, we analyzed three main outcomes, i.e., (i) recent use, (ii) lifetime use, and (iii) use duration, according to the

following criteria: (i) Recent tobacco or cannabis use was defined as a report of first-time use in the past 30 days [yes/no]. Recent alcohol use was defined as a first-time report of having

consumed alcohol at least once a month during the past year. (ii) Lifetime use was defined as the first-time report of having used tobacco or cannabis at least once in a lifetime (i.e.,

also capturing use prior to the past 30 days) or having consumed alcohol at least once in the past year (i.e., also capturing the use of less than once a month in the past year) [yes/no].

Since none of the individuals had used any substances at baseline, lifetime use referred to the entire lifetime of the individuals up to the examined point. (iii) Use duration of each

substance was calculated as the number of years reporting recent use in the 3-year follow-up (i.e., range between 0 and 3). DNA METHYLATION ANALYSIS Detailed procedures of DNA sample

preparation and DNA methylation analyses have been described previously [34]. In brief, saliva samples were collected from participants using whole-saliva collection kits (Oragene•DNA; DNA

Genotek Inc., Ottawa, Canada) and, following DNA extraction, bisulfite conversion of the DNA was performed using the EZ-96 DNA Methylation-Gold™ MagPrep kit (Zymo Research Corporation;

Irvine; USA). DNA methylation levels at the _NR3C1_ exon 1-F locus were quantified using pyrosequencing reagents on a Pyromark Q96 device (Qiagen, Hilden, Germany). Specifically, a 162-base

pair fragment was amplified using the PyroMark PCR Kit (Qiagen, Hilden, Germany) and the following primers: forward 5′- AGTTTTAGAGTGGGTTTGGAG-3′, reverse biotin-5′-CCCCCAACTCCCCAAAAA-3′.

Polymerase chain reaction conditions were optimized to yield distinct single bands and were as follows: (i) 94 °C for 15 min, (ii) 45 cycles of 94 °C for 30 s, 60 °C for 60 s and 72 °C for

30 s, and (iii) final extension at 72 °C for 10 min. The sequencing primer, 5′-GAGTGGGTTTGGAGT-3′, was used for pyrosequencing, and data were collected on five CpG sites, denoted CpGs 1–5

(Fig. 1). As shown in Fig. 1, CpGs 3 and 4 belong to a binding site of NGFI-A, as reported by McGowan et al. [13]. Our CpG numbering follows the one reported by Oberlander et al. [17], where

CpG3 was also found to associate with infant stress cortisol reactivity. Of note, CpG3 constitutes a site that is not captured by the HumanMethylation450 and the EPIC BeadChips (Illumina;

Illumina Inc., San Diego, CA, USA). For reference, we also provide the 450 K/EPIC array probe IDs that correspond to our remaining CpGs of interest: CpG1 (cg15645634), CpG2 (not captured),

CpG3 (not captured), CpG4 (cg15910486), CpG5 (cg04111177). To validate the efficiency of our primers, amplification of unmethylated and methylated control DNA samples was performed using

human HCT116 DKO Non-Methylated and Methylated DNA (Zymo Research Corporation). The percentage methylation values obtained for the unmethylated control was in the 0–4% range, and for the

fully methylated control in the 86–95% range, for all five CpGs. Water samples gave no signal. The average between-plate coefficient of variation for CpGs 1–5 was 10.3% (range: 4.5–16.2%),

calculated from control samples containing 0, 6, 9, and 12% methylated DNA, analyzed in duplicate in each plate. Most of the analyzed samples (98%) yielded methylation values within a 0–12%

range at any given CpG site, which is within the commonly reported range (0–20%) described in previous pyrosequencing studies of the same NR3C1 region using blood or saliva samples from

infants, children, and adults [15, 17, 22, 35]. In our study, correlation analyses among the five CpG sites also showed that CpG3 was the site whose DNA methylation levels correlated the

least with the remaining four sites (Fig. S1). We also provide the overall distribution of methylation levels across the five CpG sites (Fig. S2), as well as the distributions of individual

CpG methylation levels in relation (i) to sex, internalizing symptoms, and parental history of psychiatric disorders (Fig. S3) and (ii) to substance use types (Fig. S4). All our analyses

were performed blinded to the phenotypes and, for analytical purposes, methylation levels for each CpG were categorized into three groups as previously described [34], i.e.,: (i)

unmethylated: participants with no detectable methylation levels (0%); (ii) low methylation: methylation below the median of detectable methylation levels; and (iii) high methylation:

methylation above the median of detectable methylation levels. SALIVARY CORTISOL ANALYSES Salivary cortisol data were available from 320 participants at baseline. The specimen collection and

analytic procedures for salivary cortisol measurements have been described previously [36]. In brief, specimens were collected in Salivette tubes (Sarstedt, Leicester, UK) twice during the

same day; in the morning (approximately 2 h after awakening) and in the afternoon (approximately 8 h after awakening). Samples were stored at −20 °C until subsequent cortisol measurements

using an enzyme-linked immune sorbent assay (Salivary Cortisol ELISA Kit; Salimetrics, UK). Each ELISA sample was run in duplicate, with morning and afternoon samples from the same

participant run on the same 96-well plate, and cortisol concentrations were expressed in micrograms per deciliter (μg/dL). Each plate also contained a cortisol concentration standard curve,

as well as interplate controls with known cortisol concentrations, run in duplicates. The correlation coefficients of the standard curves were >0.997 with a median of 0.999 for each

plate. The control samples revealed a between-plate coefficient of variation of 7.0% and the median within-plate coefficient of variation for all participant samples was 8.1%. COVARIATES We

used information on parents’ education, birthplace, and smoking habits to examine the social characteristics of the sample. Previous literature has found that methylation of _NR3C1_ at the

exon 1-F locus is associated with internalizing, but not externalizing, behavior problems [32, 34]. Moreover, parental depression has been associated with _NR3C1_ methylation in the

offspring [17]. Thus, adolescent internalizing symptoms and parental psychiatric disorders were considered potential confounders. However, it is also important to consider another possible

causal pathway. Specifically, since internalizing symptoms can stem from a dysregulated HPA axis, internalizing symptoms may be a mediator of the association between HPA-axis dysregulation

and substance use. Thus, considering internalizing symptoms as a covariate in the models may result in over adjustment. We included self-reported internalizing symptoms (as a continuous

variable) in the 7th grade, measured according to the Center for Epidemiologic Studies Depression Scale for Children (CES-DC) [37, 38]. The CES-DC is a 20-item, internationally validated

scale used in epidemiological studies of children and adolescents (6–17 years of age), with a total score ranging from zero to 60. This score was dichotomized using a cut-off score of ≥30,

which has been found to capture internalizing problems in Swedish adolescents [38, 39]. Parental history of mental, behavioral, and neurodevelopmental disorders was retrieved from the

National Patient Register according to the International Classification of Disease (ICD) 10 codes (F01-F99) [40] and categorized as a binary variable. STATISTICAL ANALYSES We used

descriptive statistics to summarize the main characteristics of the study sample. The associations of _NR3C1_ methylation with recent substance use, lifetime substance use, and substance use

duration were assessed on a univariate level for each CpG site separately and for all sites grouped together. Poisson regression models \(\left( {\log \left( {E\left( {Y{{{\mathrm{|}}}}X}

\right)} \right) = \alpha + \beta _i \ast X_i} \right)\), with or without sex stratification, were used to derive the rate ratios (RRs) and corresponding 95% confidence intervals (CIs) for

recent use and lifetime use, and the risk ratios (RRs) and 95% CIs for substance use duration and increasing methylation during the 3-year follow-up. In all analyses, the unmethylated group

constituted the reference. Models with and without adjusting for internalizing symptoms and parental history of mental, behavioral, and neurodevelopment disorders were compared. A

sensitivity analysis was performed to analyze the potential selection bias introduced by attrition in the third follow-up (non-compulsory education, 18.6%), limiting the analyses to the

first two years of follow-up (end of the Swedish compulsory education). In addition, multilevel models were used to take into account the clustering of students within schools. As multilevel

models did not reveal heterogeneity among schools, the results were reported according to the standard regression models. Bonferroni-corrected confidence intervals were included in

sensitivity analyses to adjust for multiple testing. Confidence intervals were set at 99.2% (1-alpha/_m_, where alpha = 0.05 [type I error] and _m_ = 6 [number of tests, 5 separate CpG sites

 + CpG sites grouped together]). The goodness of fit test and graphical checks of residuals based on residual deviance did not show a major departure from Poisson model assumptions. To

quantify the effect of unmeasured potential confounding factors, we also report the _E_-values for associations between CpG 3 site/CpG 1–5 sites and substance use as outcomes. The _E_-value

represents the minimal strength of association on the RR scale that an unmeasured confounder would need to have, with both the predictor and the outcome, to fully explain the association

between the two [41]. The association between the methylation levels across the five CpG sites and cortisol levels were examined using linear regression models. Due to the small sample size

(_n_ = 320), methylation levels were considered as a binary variable (methylated vs. unmethylated group). To account for potential selection because of the sampling approach, we performed

weighted linear regression models applying an inverse probability weight method. Sex, internalizing problems, parental history of mental, behavioral, and neurodevelopmental disorders, and

school was considered in weight calculation. As the results from weighted models were not different from those obtained with standard linear regression models, they are reported according to

this latter method. The code of the statistical analysis is available from the corresponding author on request. Considering a prevalence of methylation of 50% for CpG 3 site, a sample of

1040 students is sufficient to detect a 5% increase in smoking behaviors in those methylated compared to those non-methylated with a power of 80%. The Stata software package (StataCorp. LLC;

TX, USA) was used for all statistical analyses. RESULTS PARTICIPANT CHARACTERISTICS The analytical sample consisted of _N_ = 1041 students, 13–14 years of age, without a history of

substance use at baseline. Of these students, 73.5% had at least one parent with a university education, less than 20% had an immigration background with similar distribution between sexes

(Table 1). Also, 6.2% of students presented with internalizing symptoms according to CES-DC scoring, with a higher prevalence in females than in males (9.3% vs. 2.3%), and 11.5% of students

had parents with a history of psychiatric disorders. The prevalence of methylation varied across the five analyzed CpG sites of _NR3C1_ and CpG3, which belongs to the binding site of NGFI-A

in the promoter region of _NR3C1_’s exon 1-F (Fig. 1), was the site most prone to methylation (Table 1). The distribution of methylation levels was similar according to sex and internalizing

symptoms distribution, while the parental history of psychiatric disorders was associated with higher levels of methylation at CpG sites 1–3 (Fig. S3). During the 3-year follow-up, 166

students (15.9%) reported recent use of at least one substance. Specifically, 96 students (9.2%) reported recent smoking, 56 (5.4%) recent use of snus, 103 (9.8%) recent use of alcohol, and

14 (1.3%) recent use of cannabis. Totally, 76 (7.3%) students reported recent polysubstance use (Table S1). We observed slightly higher recent use rates among females than males (18.0%

versus 13.5% for at least one substance) particularly for cigarette smoking (11.3% versus 6.7%) and alcohol consumption (12.2% versus 7.1%). With regard to lifetime use, 193 students (18.5%)

reported ever having smoked, 118 (11.3%) reported lifetime use of snus, 486 (46.7%) reported lifetime use of alcohol, and 35 (3.4%) reported lifetime use of cannabis (Table S1). With regard

to substance use duration, about 10% of students used at least one substance for 1 year, 5% for 2 years, and 1% for 3 years (Table S1). Table S2 reports descriptive statistics on the

association between DNA methylation levels and current substance use. The groups with high methylation levels for CpGs 2 and 3, and CpGs1–5, show higher current substance use. The graphical

visualization of the distribution of methylation levels confirmed this pattern, mainly for CpG site 3 (Fig. S4). NR3C1 METHYLATION PREDICTS SUBSTANCE USE IN ADOLESCENCE The results from the

Poisson regression models that compared rates of recent substance use, in terms of baseline _NR3C1_ methylation levels, are presented in Fig. 2 and Table S3. Students with high baseline DNA

methylation levels at CpG site 3 had 1.7–2.3-fold higher rates of reporting recent use of cigarettes, snus, and alcohol. The estimates across the other CpG sites (2, 4, and grouped) were

lower, although the same patterns emerged, especially for the recent use of cigarettes. Thus, high baseline methylation in the combined CpG1–5 group is associated with an increased risk for

recent cigarette use. The sensitivity analysis showed that the corresponding _E_-value for methylation at CpG site 3 (RR = 2.30) and any CpG site (RR = 1.62) as exposure, and recent

cigarette use as an outcome, were 4.03 (lower confidence limit 2.26) and 2.62 (1.21), respectively (Table S4). The multivariable-adjusted analysis for internalizing symptoms and parental

history of psychiatric disorders, along with the Bonferroni-corrected estimates, yielded similar results but with less precise estimates (Tables S5 and S6). The only exception was for

cannabis use where the confidence intervals were too wide to draw any conclusion on the direction of the association. Site- and substance-specific associations were slightly different

between sexes (Tables S7 and S8). Risk estimates were stronger for CpG site 3 in males, and CpG site 2 in females. Moreover, the associations with cigarette and alcohol use were more

pronounced in males. The overall estimates were attenuated when considering lifetime substance use as the outcome (Fig. 3 and Table S9) also considering models adjusted for parental history

of psychiatric disorders and with Bonferroni corrected estimates (Tables S10 and S11). Nonetheless, the associations remained significant between CpG site 3 and cigarette smoking or cannabis

use. Moreover, sex-stratified analyses revealed associations for lifetime cigarette use in males (CpG site 3) and lifetime cannabis use in females (CpG sites 1 and 5) (Tables S12 and S13).

NR3C1 METHYLATION PREDICTS SUBSTANCE USE DURATION IN ADOLESCENCE Baseline _NR3C1_ methylation levels were also associated with higher risk for prolonged substance use duration (i.e., number

of years reporting recent use), with the highest estimates in those with high methylation levels at CpG site 3 in both unadjusted and adjusted models (Fig. 4, Tables S14–S16). Site- and

substance-specific associations were also confirmed for the duration outcome when stratifying by sex (Tables S17 and S18). Restricting analyses to the second follow-up resulted in estimates

that were in the same direction but with wider confidence intervals (data not shown). ASSOCIATION BETWEEN NR3C1 METHYLATION AND SALIVARY CORTISOL LEVELS Finally, we examined the association

of _NR3C1_ methylation at the five CpG sites under investigation with morning or afternoon salivary cortisol levels, which were available from a subset of participants (_N_ = 320). We found

that DNA methylation levels at CpG site 3 were associated with higher morning cortisol levels. The average increase of morning cortisol level was 0.027 μg/dL [95% CI: 0.003–0.050] in the

methylation group compared to the unmethylated group. No significant associations were found for the remaining CpG sites or with afternoon cortisol levels. DISCUSSION In this prospective

cohort study of over 1000 adolescent individuals, we found that the presence of hypermethylation at the exon 1-F promoter of _NR3C1_ in early adolescence, i.e., 13–14 years of age, was

associated with an increased risk of future self-reports of recent substance use and substance use duration during the 3-year follow-up. When considering lifetime substance use as an

outcome, the overall estimates were attenuated although some significances remained. Specifically, our findings were particularly consistent for hypermethylation of CpG site 3, which belongs

to a binding site of NGFI-A and has been associated with decreased _NR3C1_ expression as part of the exon 1-F promoter region [13]. In our study, hypermethylation of CpG site 3 predicted

future self-reports of (i) recent use of any substance (i.e., tobacco products, alcohol, or cannabis), (ii) lifetime use of tobacco products (cigarettes or snus), as well as (iii) substance

use duration of any substance. Sex-stratified analyses revealed a pronounced association in males between CpG3 hypermethylation and recent use of cigarettes (RR = 5.3). The equivalent

analyses in females revealed an association between hypermethylation of CpG2 and recent tobacco use (RR = 2.31). However, hypermethylation of CpG3 was associated again with a longer duration

of tobacco use in both males and females. Adjusting for potential confounders, such as internalizing problems and parental history of mental, behavioral, and neurodevelopmental disorders,

yielded results in the same direction. Lifetime substance use can be viewed as a proxy for risk-taking behavior often observed in adolescence, and with predisposing factors that include

temperament, neurobehavioral disinhibition, and peer behaviors [42]. As such, “lifetime use” can be considered a more benign outcome since it also captures individuals who are occasional

users or have experimented with a substance on single occasions. By contrast, the transition from occasional use to a substance use disorder constitutes a maladaptive process that requires

both heavy/repeated use and genetic predispositions [43]. Thus, the frequency of recent substance use reports over the years (reflected in our study using the outcome of substance use

duration), may be a better indicator of chronic problematic substance use, which increases the risk of substance use disorders [42, 44]. Given (i) the overall attenuated estimates for

lifetime use found in our study, and given (ii) that methylation quantitative trait loci (mQTLs) may underlie our observed changes in _NR3C1_ methylation (as discussed further below), this

may indicate that _NR3C1_ is involved more in those maladaptive processes that are related to substance abuse, and less in those processes that underlie experimental or occasional use.

However, further longitudinal studies, with more detailed information on substance use behaviors, are warranted to support this hypothesis. The first evidence that _NR3C1_ may be able to

modulate the initiation of substance use, was provided by genetic studies showing a significant association between polymorphisms in the _NR3C1_ gene and alcohol use initiation in

14‐year‐old adolescents [45]. However, our study is the first to our knowledge to employ a large-scale (_N_ > 1000) longitudinal approach to examine whether _NR3C1_ methylation at the

exon 1-F locus can predict three different substance use outcomes in middle adolescence. Importantly, the use of DNA samples from individuals with no lifetime history of substance use, makes

our findings unlikely to be explained by reverse causality [46, 47]. Moreover, since previous studies had found associations between _NR3C1_ methylation and cortisol stress responses [15,

17, 20,21,22], we also examined the correlations between the five CpGs under investigation and salivary cortisol levels available from a subset of individuals. We found that DNA methylation

at CpG 3 was associated with higher morning cortisol levels. Interestingly, a previous study using cord blood samples from infants found that increased methylation at CpG3 was the only CpG

site under investigation that was associated with infant stress cortisol reactivity [17]. The same study found that exposure to increased third-trimester depressed maternal mood was also

associated with increased neonatal methylation of CpG3 [17]. Similarly, an independent study using preschoolers found that hypermethylation at the same CpG site is associated with

internalizing behavior problems [35], providing further support for the biological relevance of this CpG site and its association to stress sensitivity, HPA functioning, and risk for

psychopathology. Overall, our data suggest that saliva _NR3C1_ hypermethylation can predict substance use outcomes in middle adolescence, and are consistent with our previous findings from

the KUPOL study, which demonstrated an association between morning cortisol levels and tobacco use initiation [36]. Moreover, our findings provide support for an epigenetic predisposition

that could drive vulnerability to addiction [48]. Although no prior substance-use studies employed a longitudinal approach to investigate _NR3C1_ methylation levels in adolescents, a number

of studies used cross-sectional approaches in adult cohorts, which provide support for our findings. Specifically, two studies investigating alcohol use found hypermethylation and lower

expression of _NR3C1_ in post-mortem brain tissue of adult individuals with a history of alcohol use disorder [49, 50]. Another study investigating cocaine use found lower peripheral levels

of _NR3C1_ gene expression in adult chronic cocaine users [51]. A study using healthy adults found that a history of a _past_ substance use disorder was associated with lower peripheral

levels of _NR3C1_ methylation [52]. However, a recent study that examined adults with cannabinoid use disorders found no associations with _NR3C1_ methylation levels [53]. The specific

contributors to _NR3C1_ hypermethylation in our study participants remain unknown. Although previous studies have provided support for the hypothesis that _NR3C1_ hypermethylation in

children can result from environmental adversities, such as early life stress [54], we were not able to address this possibility since our utilized cohort did not include information on

early life adversities. Moreover, we cannot exclude the possibility that genetic variations can also influence _NR3C1_ methylation levels, similar to findings from other stress-responsive

genes such as the FK506 binding protein 5 (_FKBP5_) gene [55, 56]. Moreover, it is unlikely that methylation of _NR3C1_ is the only epigenetic predisposing factor influencing substance use

risk in adolescence. This assumption is supported by the only additional prospective study of DNA methylation and substance use risk in adolescence, to our knowledge, which included 244

individuals with methylation data from cord blood at birth and whole blood at age 7 [57]. This study by Cecil and colleagues found no link with _NR3C1_ but reported instead of an association

between substance use during adolescence and cord blood methylation of 65 loci involved in neurodevelopmental processes, including _PACSIN1_, _NEUROD4_, and _NTRK_ [57]. Nonetheless, it

should be noted that the latter study was conducted using the Illumina HumanMethylation450 BeadChip, which does not capture our main CpG site of interest, i.e., CpG3 (see also Methods).

Moreover, although Illumina and pyrosequencing data have been found to be congruent to a large extent, deviations from this congruency may still occur and caution needs to be taken for

individual loci when translating beta-values directly into percent methylation levels [58]. A number of additional limitations should be kept in mind when interpreting the results from our

study. First, the level of DNA methylation was evaluated at a single time point, making the timing of the epigenetic process unclear. Second, DNA methylation levels detected in saliva do not

necessarily correspond to those in the brain since DNA methylation signatures are often tissue-specific. Nonetheless, previous studies examining the concordance of DNA methylation across

commonly used peripheral tissues (i.e., blood, saliva, and buccal tissue) with DNA methylation in the brain, found the highest correlations to the brain with saliva, at least when the

average global correlations were used [59]. Thus, it is also important to consider the nature of the cell types present in saliva samples, which may vary based on each study’s saliva

collection kit. For instance, the epithelial cell count in saliva samples collected with the Oragene·DNA kit, used in our study, can range from 20 to 70%, with the remaining cells being

mostly leukocytes and with the age of subject being one potential determining factor (personal correspondence with DNA Genotek). Furthermore, although it is customary to assess leukocyte

cell-type distributions in blood-based DNA methylation studies, such cell-type assessments are not made possible in saliva samples already collected with the Oragene·DNA kit that utilizes

lytic chemistry, meaning it will lyse most cells in the sample and degrade/denature proteins. To address this limitation, future studies can consider collecting a small amount of saliva into

a separate tube for cell sorting, since raw saliva samples can be used to perform cell-sorting assays and can be smeared on a slide to enumerate cells by microscopy. Nonetheless, it is

reassuring that the majority of our analyzed samples yielded methylation values within the commonly reported range described in previous pyrosequencing studies of _NR3C1_ using blood or

saliva samples [15, 17, 22, 35]. Third, the number of participants with drug use was relatively small, which could affect the precision of the results. In addition, self-reported substance

use tends to underestimate actual use [60, 61]. Fourth, randomness in methylation can affect measurement precision, while systematic measurement errors may bias estimates towards or away

from the null. Nonetheless, the large sample size contributed to reducing the role of random errors on final estimates. However, the small number of cases for cannabis use did not always

allow reaching conclusions on estimated directions. Moreover, possible measurement errors of methylation are unlikely to have occurred differentially according to substance use. Hence,

nondifferential misclassification would likely result in an underestimation of the associations under examination. Along the same lines, misclassification of substance use is unlikely to

have differed according to methylation levels. Nonetheless, caution needs to be taken when interpreting results from substance use duration, since a value of 1 at the first follow-up may

differ in meaning from a value of 1 at the third follow-up. Specifically, the former may indicate experimental use if it is not followed by substance use in the second follow-up, while the

latter may indicate either experimental use or the beginning of chronic use depending on substance intake during the subsequent (unstudied) years. Finally, unmeasured, unknown, or residual

confounding could not be excluded, for instance, due to parenting style and genetic liability to substance dependence. Consequently, we performed a sensitivity analysis to estimate the

magnitude of confounding (Table S4). For example, the observed RR of 1.62 (between grouped CpG sites and recent cigarette use) could be explained by an unmeasured confounder that was

associated both with the exposure and the outcome by a RR of 2.62 each (_E_-value), above and beyond the measured confounders. The confidence interval could be moved to include the null by

an unmeasured confounder that was associated both with the exposure and with the outcome by a RR of 1.21 each, above and beyond the measured confounders. Overall, _E_-values support the

robustness of the present findings. Indeed, genetic factors in the form of single nucleotide polymorphisms (SNPs) represent the main possible confounders in the pathway between HPA axis

dysregulation and substance use. However, it is unlikely that the magnitude of the association between a single SNP and both exposure/outcome will be higher than 2.62, given that psychiatric

traits are most polygenic, involving a continuum of small effects, and SNP heritability accounts for modest percentages in substance use behaviors [43, 62, 63]. Despite these limitations,

our study also had notable strengths. It was based on a large longitudinal cohort with low attrition at first and second follow-ups (8.9% and 12.7%, respectively), thus minimizing the risk

of reverse causality due to DNA methylation changes caused by substance use [64]. DNA methylation was assessed in early adolescence, a period when the use of substances is usually not yet

established, and the few subjects that reported substance use at baseline were excluded. Moreover, outcome information was assessed during three consecutive years. The adjustment was also

made for internalizing symptoms and parental history of mental, behavioral, and neurodevelopmental disorders at baseline, which were treated as potential confounders. However, it should also

be noted that controlling for internalizing symptoms may result in over-adjustment due to a possible causal pathway from _NR3C1_ methylation to internalizing symptoms to substance use.

Conclusively, our findings indicate that _NR3C1_ methylation levels can predict substance use outcomes in adolescence. However, additional longitudinal studies are warranted to confirm these

findings and to investigate the role of genes versus environment in affecting _NR3C1_ methylation. CODE AVAILABILITY The code of the statistical analysis is available under request to the

corresponding author (http://[email protected]). REFERENCES * Crews F, He J, Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol Biochem

Behav. 2007;86:189–99. Article  CAS  PubMed  Google Scholar  * Jordan CJ, Andersen SL. Sensitive periods of substance abuse: early risk for the transition to dependence. Dev Cognit Neurosci.

2017;25:29–44. Article  Google Scholar  * Grant BF. Age at smoking onset and its association with alcohol consumption and DSM-IV alcohol abuse and dependence: results from the National

Longitudinal Alcohol Epidemiologic Survey. J Subst Abus. 1998;10:59–73. Article  CAS  Google Scholar  * Clark DB, Lesnick L, Hegedus AM. Traumas and other adverse life events in adolescents

with alcohol abuse and dependence. J Am Acad Child Adolesc Psychiatry. 1997;36:1744–51. Article  CAS  PubMed  Google Scholar  * Dube SR, Felitti VJ, Dong M, Chapman DP, Giles WH, Anda RF.

Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse childhood experiences study. Pediatrics 2003;111:564–72. Article  PubMed  Google Scholar  *

Bensley LS, Spieker SJ, Van Eenwyk J, Schoder J. Self-reported abuse history and adolescent problem behaviors. II. Alcohol and drug use. J Adolesc Health. 1999;24:173–80. Article  CAS 

PubMed  Google Scholar  * Alves RL, Oliveira P, Lopes IM, Portugal CC, Alves CJ, Barbosa F, et al. Early-life stress affects drug abuse susceptibility in adolescent rat model independently

of depression vulnerability. Sci Rep. 2020;10:13326. Article  CAS  PubMed  PubMed Central  Google Scholar  * Andersen SL. Stress, sensitive periods, and substance abuse. Neurobiol Stress.

2019;10:100140. Article  PubMed  Google Scholar  * Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and

preparative actions. Endocr Rev. 2000;21:55–89. CAS  PubMed  Google Scholar  * Wang D, Levine JLS, Avila-Quintero V, Bloch M, Kaffman A. Systematic review and meta-analysis: effects of

maternal separation on anxiety-like behavior in rodents. Transl Psychiatry. 2020;10:174. Article  PubMed  PubMed Central  Google Scholar  * Weaver IC, Cervoni N, Champagne FA, D’Alessio AC,

Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847–54. Article  CAS  PubMed  Google Scholar  * Cicchetti D, Handley ED. Methylation of the

glucocorticoid receptor gene, nuclear receptor subfamily 3, group C, member 1 (NR3C1), in maltreated and nonmaltreated children: associations with behavioral undercontrol, emotional

lability/negativity, and externalizing and internalizing symptoms. Dev Psychopathol. 2017;29:1795–806. Article  PubMed  PubMed Central  Google Scholar  * McGowan PO, Sasaki A, D’Alessio AC,

Dymov S, Labonté B, Szyf M, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci. 2009;12:342–48. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Perroud N, Paoloni-Giacobino A, Prada P, Olié E, Salzmann A, Nicastro R, et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with

a history of childhood maltreatment: a link with the severity and type of trauma. Transl Psychiatry. 2011;1:e59. Article  CAS  PubMed  PubMed Central  Google Scholar  * Tyrka AR, Price LH,

Marsit C, Walters OC, Carpenter LL. Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. PLoS ONE.

2012;7:e30148–e48. Article  CAS  PubMed  PubMed Central  Google Scholar  * Melas PA, Wei Y, Wong CC, Sjöholm LK, Åberg E, Mill J, et al. Genetic and epigenetic associations of MAOA and NR3C1

with depression and childhood adversities. Int J Neuropsychopharmacol. 2013;16:1513–28. Article  CAS  PubMed  Google Scholar  * Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S,

Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. Epigenetics 2008;3:97–106.

Article  PubMed  Google Scholar  * van der Knaap LJ, Riese H, Hudziak JJ, Verbiest MM, Verhulst FC, Oldehinkel AJ, et al. Glucocorticoid receptor gene (NR3C1) methylation following stressful

events between birth and adolescence. The TRAILS study. Transl Psychiatry. 2014;4:e381. Article  PubMed  PubMed Central  Google Scholar  * Farrell C, Doolin K, O’ Leary N, Jairaj C, Roddy

D, Tozzi L, et al. DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to

early life emotional abuse. Psychiatry Res. 2018;265:341–48. Article  CAS  PubMed  Google Scholar  * Lewis CR, Breitenstein RS, Henderson A, Sowards HA, Piras IS, Huentelman MJ, et al. Harsh

parenting predicts novel HPA receptor gene methylation and NR3C1 methylation predicts cortisol daily slope in middle childhood. Cell Mol Neurobiol. 2021;41:783–93. Article  CAS  PubMed 

Google Scholar  * Conradt E, Fei M, LaGasse L, Tronick E, Guerin D, Gorman D, et al. Prenatal predictors of infant self-regulation: the contributions of placental DNA methylation of NR3C1

and neuroendocrine activity. Front Behav Neurosci. 2015;9:130. Article  PubMed  PubMed Central  Google Scholar  * Alexander N, Kirschbaum C, Wankerl M, Stauch BJ, Stalder T,

Steudte-Schmiedgen S, et al. Glucocorticoid receptor gene methylation moderates the association of childhood trauma and cortisol stress reactivity. Psychoneuroendocrinology 2018;90:68–75.

Article  CAS  PubMed  Google Scholar  * al’Absi M, Lemieux A, Westra R, Allen S. Early life adversity influences stress response association with smoking relapse. Psychopharmacology

2017;234:3375–84. Article  PubMed  PubMed Central  Google Scholar  * Lovallo WR. The hypothalamic-pituitary-adrenocortical axis in addiction. Int J Psychophysiol. 2006;59:193–4. Article 

PubMed  PubMed Central  Google Scholar  * Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann N Y Acad Sci. 2008;1141:105–30. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Buchmann AF, Laucht M, Schmid B, Wiedemann K, Mann K, Zimmermann US. Cigarette craving increases after a psychosocial stress test and is related to cortisol stress response but

not to dependence scores in daily smokers. J Psychopharmacol (Oxf, Engl). 2010;24:247–55. Article  CAS  Google Scholar  * Sinha R. The role of stress in addiction relapse. Curr Psychiatry

Rep. 2007;9:388–95. Article  PubMed  Google Scholar  * Srinivasan S, Shariff M, Bartlett SE. The role of the glucocorticoids in developing resilience to stress and addiction. Front

Psychiatry. 2013;4:68. Article  PubMed  PubMed Central  Google Scholar  * Goldfarb EV, Sinha R. Drug-induced glucocorticoids and memory for substance use. Trends Neurosci. 2018;41:853–68.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Ambroggi F, Turiault M, Milet A, Deroche-Gamonet V, Parnaudeau S, Balado E, et al. Stress and addiction: glucocorticoid receptor in

dopaminoceptive neurons facilitates cocaine seeking. Nat Neurosci. 2009;12:247–9. Article  CAS  PubMed  Google Scholar  * McGinn MA, Tunstall BJ, Schlosburg JE, Gregory-Flores A, George O,

de Guglielmo G, et al. Glucocorticoid receptor modulators decrease alcohol self-administration in male rats. Neuropharmacology 2021;188:108510. Article  CAS  PubMed  Google Scholar  *

Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, et al. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin

Investig. 2015;125:3193–7. Article  PubMed  PubMed Central  Google Scholar  * Galanti MR, Hultin H, Dalman C, Engström K, Ferrer-Wreder L, Forsell Y, et al. School environment and mental

health in early adolescence—a longitudinal study in Sweden (KUPOL). BMC Psychiatry. 2016;16:243. Article  PubMed  PubMed Central  Google Scholar  * Efstathopoulos P, Andersson F, Melas PA,

Yang LL, Villaescusa JC, Rȕegg J, et al. NR3C1 hypermethylation in depressed and bullied adolescents. Transl Psychiatry. 2018;8:121. Article  PubMed  PubMed Central  Google Scholar  * Parade

SH, Ridout KK, Seifer R, Armstrong DA, Marsit CJ, McWilliams MA, et al. Methylation of the glucocorticoid receptor gene promoter in preschoolers: links with internalizing behavior problems.

Child Dev. 2016;87:86–97. Article  PubMed  PubMed Central  Google Scholar  * Raffetti E, Landgren AJ, Andersson F, Donato F, Lavebratt C, Forsell Y, et al. Cortisol concentration as

predictor of tobacco initiation in adolescents: results from a population-based Swedish cohort. J Adolesc Health. 2021;68:758–64. Article  PubMed  Google Scholar  * Olsson G, von Knorring

AL. Depression among Swedish adolescents measured by the self-rating scale Center for Epidemiology Studies-Depression Child (CES-DC). Eur Child Adolesc Psychiatry. 1997;6:81–7. CAS  PubMed 

Google Scholar  * Fendrich M, Weissman MM, Warner V. Screening for depressive disorder in children and adolescents: validating the Center for Epidemiologic Studies Depression Scale for

Children. Am J Epidemiol. 1990;131:538–51. Article  CAS  PubMed  Google Scholar  * Olsson G, von Knotting AL. Depression among Swedish adolescents measured by the self rating scale Center

for Epidemiology Studies - Depression Child (CES-DC). Eur Child Adolesc Psychiatry. 1997;6:81–7. CAS  PubMed  Google Scholar  * Giordano G, Colaneri M, Di Filippo A, Blanchini F, Bolzern P,

De Nicolao G, et al. Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy. Nat Med. 2021;27:993–98. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Vanderweele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268–74. Article  PubMed  Google

Scholar  * Hanson KL, Medina KL, Padula CB, Tapert SF, Brown SA. Impact of adolescent alcohol and drug use on neuropsychological functioning in young adulthood: 10-year outcomes. J Child

Adolesc Subst Abus. 2011;20:135–54. Article  Google Scholar  * Kranzler HR, Zhou H, Kember RL, Smith RV, Justice AC, Damrauer S, et al. Author correction: genome-wide association study of

alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019;10:4050. Article  PubMed  PubMed Central  Google Scholar  * Lewinsohn PM, Rohde P,

Brown RA. Level of current and past adolescent cigarette smoking as predictors of future substance use disorders in young adulthood. Addiction. 1999;94:913–21. Article  CAS  PubMed  Google

Scholar  * Desrivières S, Lourdusamy A, Müller C, Ducci F, Wong CP, Kaakinen M, et al. Glucocorticoid receptor (NR3C1) gene polymorphisms and onset of alcohol abuse in adolescents. Addiction

Biol. 2011;16:510–3. Article  Google Scholar  * Philibert RA, Beach SR, Brody GH. The DNA methylation signature of smoking: an archetype for the identification of biomarkers for behavioral

illness. Neb Symp Motiv Neb Symp Motiv. 2014;61:109–27. Google Scholar  * Zakhari S. Alcohol metabolism and epigenetics changes. Alcohol Res. 2013;35:6–16. PubMed  PubMed Central  Google

Scholar  * Nielsen DA, Utrankar A, Reyes JA, Simons DD, Kosten TR. Epigenetics of drug abuse: predisposition or response. Pharmacogenomics. 2012;13:1149–60. Article  CAS  PubMed  Google

Scholar  * McClintick JN, Xuei X, Tischfield JA, Goate A, Foroud T, Wetherill L, et al. Stress-response pathways are altered in the hippocampus of chronic alcoholics. Alcohol.

2013;47:505–15. Article  CAS  PubMed  Google Scholar  * Gatta E, Grayson DR, Auta J, Saudagar V, Dong E, Chen Y, et al. Genome-wide methylation in alcohol use disorder subjects: implications

for an epigenetic regulation of the cortico-limbic glucocorticoid receptors (NR3C1). Mol Psychiatry. 2021;26:1029–41. Article  CAS  PubMed  Google Scholar  * Schote AB, Jäger K, Kroll SL,

Vonmoos M, Hulka LM, Preller KH, et al. Glucocorticoid receptor gene variants and lower expression of NR3C1 are associated with cocaine use. Addiction Biol. 2019;24:730–42. Article  CAS 

Google Scholar  * Tyrka AR, Parade SH, Welch ES, Ridout KK, Price LH, Marsit C, et al. Methylation of the leukocyte glucocorticoid receptor gene promoter in adults: associations with early

adversity and depressive, anxiety and substance-use disorders. Transl Psychiatry. 2016;6:e848. Article  CAS  PubMed  PubMed Central  Google Scholar  * Pehlivan S, Aytac HM, Cetinay Aydin P,

Nursal AF, Pehlivan M. Global and glucocorticoid receptor gene-specific (NR3C1) DNA methylation analysis in patients with cannabinoid or synthetic cannabinoid use disorder. Psychiatry Res.

2021;298:113774. Article  CAS  PubMed  Google Scholar  * Parade SH, Huffhines L, Daniels TE, Stroud LR, Nugent NR, Tyrka AR. A systematic review of childhood maltreatment and DNA

methylation: candidate gene and epigenome-wide approaches. Transl Psychiatry. 2021;11:134. Article  PubMed  PubMed Central  Google Scholar  * Klengel T, Mehta D, Anacker C, Rex-Haffner M,

Pruessner JC, Pariante CM, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci. 2013;16:33–41. Article  CAS  PubMed  Google Scholar  *

Klinger-König J, Hertel J, Van der Auwera S, Frenzel S, Pfeiffer L, Waldenberger M, et al. Methylation of the FKBP5 gene in association with FKBP5 genotypes, childhood maltreatment and

depression. Neuropsychopharmacology. 2019;44:930–8. Article  PubMed  PubMed Central  Google Scholar  * Cecil CA, Walton E, Smith RG, Viding E, McCrory EJ, Relton CL, et al. DNA methylation

and substance-use risk: a prospective, genome-wide study spanning gestation to adolescence. Transl Psychiatry. 2016;6:e976. Article  CAS  PubMed  PubMed Central  Google Scholar  * Roessler

J, Ammerpohl O, Gutwein J, Hasemeier B, Anwar SL, Kreipe H, et al. Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina, Inc. BMC Res Notes.

2012;5:210. Article  CAS  PubMed  PubMed Central  Google Scholar  * Braun PR, Han S, Hing B, Nagahama Y, Gaul LN, Heinzman JT, et al. Genome-wide DNA methylation comparison between live

human brain and peripheral tissues within individuals. Transl Psychiatry. 2019;9:47. Article  PubMed  PubMed Central  Google Scholar  * Connor Gorber S, Schofield-Hurwitz S, Hardt J,

Levasseur G, Tremblay M. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res.

2009;11:12–24. Article  PubMed  Google Scholar  * Jain R, Jhanjee S, Jain V, Gupta T, Mittal S, Chauhan P, et al. Biochemical validation of self-reported smokeless tobacco abstinence among

smokeless tobacco users: results from a clinical trial of varenicline in India. J Psychoact Drugs. 2015;47:331–5. Article  Google Scholar  * Zhang Y, Qi G, Park JH, Chatterjee N. Estimation

of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. Nat Genet. 2018;50:1318–26. Article  CAS  PubMed  Google

Scholar  * Liu M, Jiang Y, Wedow R, Li Y, Brazel DM, Chen F, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol

use. Nat Genet. 2019;51:237–44. Article  CAS  PubMed  PubMed Central  Google Scholar  * Sugden K, Hannon EJ, Arseneault L, Belsky DW, Broadbent JM, Corcoran DL, et al. Establishing a

generalized polyepigenetic biomarker for tobacco smoking. Transl Psychiatry. 2019;9:92. Article  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS The authors

would like to thank the participating adolescents, families, and schools, and the executive team of the KUPOL study who make our research possible. The KUPOL study is funded by a grant (No.

259-2012-48) containing funds from the Swedish Research Council Formas, the Swedish Research Council for Health, Working Life and Welfare, and the Swedish Research Council-Vetenskapsrådet

awarded to M.R.G. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the article. FUNDING Open access funding provided by

Karolinska Institute. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden Elena Raffetti, Filip Andersson, Yvonne

Forsell & Maria Rosaria Galanti * Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm, Sweden

Philippe Anastasios Melas * Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden Philippe Anastasios Melas & Catharina Lavebratt * Region Västra Götaland,

Research and Development Primary Health Care, Gothenburg, Sweden Anton Jonatan Landgren * Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy,

University of Gothenburg, Gothenburg, Sweden Anton Jonatan Landgren * Centre for Epidemiology and Community Medicine, Stockholm Health Care District, Stockholm Region, Stockholm, Sweden

Filip Andersson, Yvonne Forsell & Maria Rosaria Galanti * Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Catharina Lavebratt Authors * Elena

Raffetti View author publications You can also search for this author inPubMed Google Scholar * Philippe Anastasios Melas View author publications You can also search for this author

inPubMed Google Scholar * Anton Jonatan Landgren View author publications You can also search for this author inPubMed Google Scholar * Filip Andersson View author publications You can also

search for this author inPubMed Google Scholar * Yvonne Forsell View author publications You can also search for this author inPubMed Google Scholar * Catharina Lavebratt View author

publications You can also search for this author inPubMed Google Scholar * Maria Rosaria Galanti View author publications You can also search for this author inPubMed Google Scholar

CONTRIBUTIONS E.R., C.L., Y.F., and M.R.G. conceived the study, E.R., P.A.M., A.J.L., and M.R.G. designed the analysis. C.L. analyzed the methylation data, E.R. and F.A. performed the

statistical analysis. P.A.M. and E.R. prepared the figure. E.R. wrote the first draft of the paper, to which all authors contributed. All authors revised the final paper. CORRESPONDING

AUTHOR Correspondence to Elena Raffetti. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains

neutral with regard to jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTAL TABLES AND FIGURES RIGHTS AND PERMISSIONS OPEN ACCESS

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as

long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third

party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the

article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright

holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Raffetti, E., Melas, P.A., Landgren,

A.J. _et al._ DNA methylation of the glucocorticoid receptor gene predicts substance use in adolescence: longitudinal data from over 1000 young individuals. _Transl Psychiatry_ 11, 477

(2021). https://doi.org/10.1038/s41398-021-01601-6 Download citation * Received: 14 August 2021 * Revised: 19 August 2021 * Accepted: 01 September 2021 * Published: 15 September 2021 * DOI:

https://doi.org/10.1038/s41398-021-01601-6 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative